Pieris Pharmaceuticals Inc (PIRS) 3.24 $PIRS 5 Stocks

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pieris Pharmaceuticals Inc (PIRS) 3.24 $PIRS

5 Stocks Under $10 Set to Soar -- Must-See Charts
at The Street - Thu Jul 16, 10:19AM CDT
Here's a technical look at how to trade five stocks under $10 that look to be setting up to break out.
PIRS: 3.24 (+0.05), MBII: 1.91 (-0.01), ESI: 5.14 (+0.24), SYRX: 1.73 (+0.01), BLFS: 2.20 (+0.04)

OTC Markets Group Announces Second Quarter 2015 Index Performance and Rebalancing
PR Newswire - Thu Jul 16, 6:00AM CDT
OTC Markets Group Inc. ("OTC Markets Group" or "the Company" (OTCQX: OTCM) today announced the second quarter 2015 performance and quarterly rebalancing of the OTCQX® indexes, the OTCQB® Venture Index, the OTCM QX ADR Index ("OTCQX30" and the OTCM ADR Index.
CETX: 2.88 (-0.03), PIRS: 3.24 (+0.05), RELY: 11.13 (-0.14), CRBP: 2.06 (+0.01), ONCS: 6.29 (+0.26), CYNA: 16.54 (+0.02), BPMX: 2.34 (+0.22), CXRX: 79.73 (+1.72)

Pieris to Receive Seventh Milestone Payment From Daiichi Sankyo Collaboration to Develop Anticalin(R) Therapeutics
Marketwired - Wed Jul 08, 7:02AM CDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today it will receive its third milestone payment for the second program in its discovery and development collaboration with Daiichi Sankyo Company, Limited ("Daiichi Sankyo", and seventh milestone payment overall under the multi program collaboration. The amount of payment was not disclosed. The payment was triggered by the achievement of positive in vivo proof of concept data and progression of the Anticalin drug candidate through a non-GLP toxicity study in non-human primates.
PIRS: 3.24 (+0.05)

Pieris Pharmaceuticals Closes Public Offering of Common Stock
Marketwired - Mon Jul 06, 2:59PM CDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, today announced the closing of a public offering of 9,090,909 shares of its common stock at a public offering price of $2.75 per share.
PIRS: 3.24 (+0.05)

Premarket Gainers / Losers as of 9:15 am
Seeking Alpha - at Seeking Alpha - Tue Jun 30, 8:19AM CDT

FIT: 45.65 (+1.72), PIRS: 3.24 (+0.05), KITE: 72.15 (+3.29), SRPT: 32.34 (+0.34), WSH: 46.25 (+0.22), CALA: 8.10 (-0.33), CLLS: 36.27 (+1.40), LBIO: 8.94 (+0.15), JUNO: 48.92 (+1.12), PNR: 59.38 (+0.63), APOL: 13.49 (+0.14), DSKX: 3.30 (-0.01)

Pieris Pharmaceuticals Prices Public Offering of Common Stock
Marketwired - Tue Jun 30, 7:02AM CDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, today announced the pricing of a public offering of 9,090,909 shares of its common stock at a public offering price of $2.75 per share. All shares of common stock are being offered by the company. In addition, Pieris has granted the underwriters a 30-day option to purchase up to an additional 1,363,636 shares of common stock at the same price to cover any over-allotments.
PIRS: 3.24 (+0.05)

Week Ahead: Get Ready For A Dose Of High-Growth Healthcare With 7 IPOs
Renaissance Capital IPO Research - Seeking Alpha - Mon Jun 29, 1:40AM CDT
As many as 7 companies could go public in the US during the shortened holiday week. The week's three high-growth health care IPOs that are on the IPO calendar should receive the most interest, especially after device maker Glaukos (Pending: GKOS )...
CNXC: 14.87 (+0.20), PIRS: 3.24 (+0.05), TDOC: 30.84 (-0.47), CFMS: 22.60 (-0.53), NTRA: 18.01 (+0.01)

Week Ahead: As Many As 16 IPOs Could Price During The Week Of June 22
Renaissance Capital IPO Research - Seeking Alpha - Mon Jun 22, 10:31AM CDT
16 companies are on the calendar to go public this week and raise $2.5 billion. It should be the year's most active week in the IPO market; the second busiest week saw 10 IPOs in January. Investors have plenty of options this week, so expect IPO...
TRU: 24.45 (+0.06), PIRS: 3.24 (+0.05), CATB: 12.88 (+0.88), WNFM: (), GKOS: 30.17 (-0.44), APPF: 14.55 (+0.40), LNTH: 6.54 (+0.01), YECO: 3.85 (-0.18), MCRN: 19.39 (+0.34), ALRM: 17.21 (+0.06), MCRB: 36.27 (+1.22)

Pieris Pharmaceuticals on deck for IPO and uplisting
Seeking Alpha - at Seeking Alpha - Fri Jun 19, 3:39PM CDT

PIRS: 3.24 (+0.05)

Pieris Pharmaceuticals Completes Dosing of Healthy Volunteers in Phase I Clinical Trial for Anticalin Program in Anemia
Marketwired - Wed Jun 10, 7:02AM CDT
Pieris Pharmaceuticals, Inc. (OTCQB: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today the completion of enrollment of healthy subjects in a blinded, placebo-controlled Phase I clinical trial for the Company's PRS-080 program, a hepcidin antagonist to treat anemia. This study was conducted at a single site in Germany.
PIRS: 3.24 (+0.05)

Recent News Highlights Pieris's Efforts In Immuno-Oncology
Jason Napodano, CFA - at Seeking Alpha - Fri May 22, 6:36AM CDT

PIRS: 3.24 (+0.05)

Pieris Pharmaceuticals to Present Data on Novel Anti-CD137 and HER2 Bispecific Immuno-Oncology Program at UBS Global Healthcare Conference
Marketwired - Tue May 19, 6:31AM CDT
Pieris Pharmaceuticals, Inc. (OTCQB: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today that President and CEO, Stephen Yoder, will present preclinical data on a new immuno-oncology program -- an Anticalin-based CD137-HER2 bispecific -- at the UBS Global Healthcare Conference at 4:30 pm EDT.
PIRS: 3.24 (+0.05)

Pieris Pharmaceuticals Appoints Immuno-Oncology Expert, Holbrook Kohrt, M.D., Ph.D., to Spearhead Immuno-Oncology Efforts and Initiates Research Collaboration With Leading Cancer Research Center
Marketwired - Thu May 14, 7:30AM CDT
Pieris Pharmaceuticals, Inc. (OTCQB: PIRS), a biotechnology company advancing its patented and proprietary Anticalin® biotherapeutic technologies, announced today that it has engaged Dr. Holbrook Kohrt, M.D., Ph.D. as Senior Advisor Translational Medicine Immuno-oncology.
PIRS: 3.24 (+0.05)

Pieris Pharmaceuticals Reports First Quarter 2015 Financial Results
Marketwired - Wed May 13, 4:30PM CDT
Pieris Pharmaceuticals, Inc. (OTCQB: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, reported today financial results for the first quarter ended March 31, 2015 and provided an update on the Company's recent developments.
PIRS: 3.24 (+0.05)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 151

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 109

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Radiotherapy Suit Challenges New EviCore Guidelines

Updated Category News Views 43

Turning Up the Heat on EviCore Winter Park, Florida—home of sunshine, oranges, and now a heated legal standoff. On November 16, 2026, the Radiotherapy Access Alliance dropped a bombshell lawsuit against EviCore over its recent guideline flip-flop. EviCore reversed its stance on low-dose radiation therapy (LDRT) for arthritis and other pesky pain, leaving patients—and...

Continue Reading
DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 16

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading
Engrain's Geospatial Innovation Pushes Property Mapping Forward

Updated Category News Views 21

Pushing the Boundaries of Property Mapping How far can you expand the boundaries of property mapping tech? Well, Engrain seems hell-bent on finding out by cranking their innovations up a notch. The Denver-based stalwart in interactive mapping is rolling out some mind-boggling enhancements that could redefine how the multifamily housing sector operates. This isn't just...

Continue Reading
Flexible Packaging Market to Hit $384.32B by 2031

Updated Category News Views 17

Packaging's Flexible Future Alright, here's the skinny: you might want to adjust those portfolios if you're watching the materials sector, because the flexible packaging market ain't just loosening up—it's stretching out like never before. By 2031, we're talking about it raking in a solid $384.32 billion, climbing from $313.25 billion in 2026. That's a not-so-shabby...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 34

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
SwitchBot's Hub 4: A Step Toward a Connected Future

Updated Category News Views 24

Turning a House Into a Smart Home Haven Out of Tokyo and onto the world stage, SwitchBot's got something new cooking that might just shake up the smart home scene. They've launched the Hub 4, a gadget that's like the Swiss Army knife of home control. For those who like things simple, this is a one-hub-to-rule-them-all kind of deal. 101,000 Reasons to Notice Now, they...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 49

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 362

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating a Milestone: Gifting the 400th Home to a Veteran

Updated Category News Views 339

Celebrating a Milestone with 400th Home Gift Building Homes for Heroes and Hillwood Properties proudly partnered to celebrate a significant milestone by gifting a home to U.S. Army Specialist Joshua Sager and his family. This remarkable achievement signifies the organization’s commitment to providing veterans and first responders with the means to establish a fresh...

Continue Reading
Wheeler REIT Achieves Record Price as Growth Continues

Updated Category News Views 259

Wheeler REIT Reaches New Milestone In an extraordinary demonstration of resilience and upward momentum, Wheeler Real Estate Investment Trust (WHLRD) has achieved a remarkable milestone by hitting a 52-week high of $27.49 USD. This achievement reflects the company's strong performance and investor confidence in its strategic direction. Strong Financial Position Recent data...

Continue Reading
S&P Global Splits Off Mobility Unit: Investor View

Updated Category News Views 52

Strategic Moves Shake Up S&P Global Listen up, traders! You don’t want to miss what S&P Global, ticker NYSE:SPGI, is cooking up. They've given the green light to split off their Mobility division, officially birthing Mobility Global Inc. This shake-up promises to stir some excitement in the market. Buckle up, because here's what this movement means for you and your...

Continue Reading
Carvana's Q3 Earnings Surge Promises Bright Future for CVNA

Updated Category News Views 103

Carvana Shares Soar After Impressive Q3 Earnings Report Recently, Carvana (NYSE: CVNA), a leading online used-car retailer, experienced a significant surge in its stock price as a result of a positive earnings announcement for the third quarter. The encouraging outlook provided by the company has delighted investors, pushing shares upward during premarket trading....

Continue Reading
PHINIA Unveils Comprehensive Guide to International Emission Standards

Updated Category News Views 150

PHINIA Unveils New Emission Standards Guide for 2024/25 PHINIA Inc. (NYSE: PHIN), a leading name in premium fuel systems and electrical solutions, has launched its latest 2024/25 Emission Standards Booklet specifically designed for heavy-duty and off-road vehicles, engines, and machinery. This guide is unique as it serves as the only complete resource available to keep...

Continue Reading